BioSpace News Archive

Artificial retina is a device which consists of an array of microelectrodes. The device is implanted into the eyes of people who are blind due to retinal diseases.

Anti-neprilysin medications are used in the treatment of a wide range of health conditions including renal diseases, heart failure, and hypertension.

Cathepsin B is an important mediator of inflammation and programmed cell death in individual cells. It has a role in inducing cell dissolution and recycling of cellular organelles.

Allele Biotechnology and Pharmaceuticals, Inc. has been using mRNA as its core technology for creating cGMP-grade iPSC lines for regenerative medicine and oncology for over a decade.

bluebird bio, Inc. announced that the European Medicines Agency accepted the company’s marketing authorization application for its investigational elivaldogene autotemcel gene therapy for the treatment of patients with cerebral adrenoleukodystrophy.

Co-Diagnostics, Inc. announced that Access Genetics, LLC dba OralDNA® Labs, a CLIA-certified customer who uses the Company’s Logix Smart™ COVID-19 kit in their FDA authorized OraRisk® COVID-19 RT-PCR test, recently received an amended Emergency Use Authorization allowing testing from a saline oral rinse collection.

New Heat Extraction Scientific Testing Method and Technology Improves COVID-19 Molecular Test Efficiency and Throughput

Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 2,100 shares of Calithera’s common stock, at a per share exercise price of $3.45, the closing trading price on September 30, 2020.

Plus Therapeutics, Inc., announced the appointment of five leading experts in the fields of neurological surgery and neuro-oncology to its Clinical Advisory Board.

Progressive Care Inc., a personalized healthcare services and technology company, announced operational performance data for August 2020, which was flat to down on a year-over-year basis due to a resurgence of Covid-19 factors driving providers to reduce patient visits.